leisure time -WSS

leisure time

author：entertainment 2025-08-31 21:00:56 - browse：775

Truvian Health employee with a plate holding reagents used to measure commonly tested blood markers. Truvian

SAN DIEGO — Truvian Health, a San Diego blood diagnostics company, shared data on Tuesday showing that its benchtop instrument’s results are largely consistent with those generated by large central laboratories. But while the results lend support for the company’s vision of decentralized and widely available clinical testing, they also resurface questions about the value of an approach widely associated with the now defunct and notorious Bay Area startup Theranos.

In a multisite study, the company tested nearly 240 blood samples from healthy donors and chronic disease patients for dozens of blood-based measurements commonly ordered by doctors, from cholesterol to blood sugar to blood cell counts. Results from Truvian’s benchtop analytical instrument, with few exceptions, closely matched readings from devices used in large central labs and made by Swiss pharma giant Roche and Japanese firm Sysmex.

The findings were presented at the annual meeting of the American Association for Clinical Chemistry, recently rebranded as the Association for Diagnostics & Laboratory Medicine. It’s the first time Truvian has shared clinical data on its product, though they have not been published in a peer-reviewed journal. The company, which is planning additional validation studies, expects to submit for Food and Drug Administration approval of its device by the third quarter of 2024.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Twill hunts for pharma partner to market its depression app

focus

knowledge

WSS

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Gene therapy’s promise and the high cost of hope

15 die by electrocution after transformer explodes in northern India

All of Us, NIH's precision medicine initiative, gets a big boost

Readout LOUD podcast: ESMO highlights & Roivant's big deal

All of Us, NIH's precision medicine initiative, gets a big boost

entertainment

leisure time

explore

Guidelines to prevent youth baseball injuries need more muscle

How to convince healthy people to buy insurance

Apple is now the first public company to be valued at $3 trillion

A Theranos scientist

As demand for Covid shots wanes, Moderna seeks its next success

A Theranos scientist

Anesthesiologist group: stop taking Ozempic before surgery

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Duchenne breakthrough therapy leaves behind pioneering families

More hospitals are billing patients as online messages surge

Wikipedia

Lung cancer screening guidelines updated for cigarette smokers

BridgeBio heart drug succeeds in pivotal study

15 die by electrocution after transformer explodes in northern India

Life sciences investors close nearly $6 billion in new funds

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

How to convince healthy people to buy insurance

entertainment

focus

knowledge

knowledge